CN110806486A - Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 - Google Patents
Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 Download PDFInfo
- Publication number
- CN110806486A CN110806486A CN201911159971.XA CN201911159971A CN110806486A CN 110806486 A CN110806486 A CN 110806486A CN 201911159971 A CN201911159971 A CN 201911159971A CN 110806486 A CN110806486 A CN 110806486A
- Authority
- CN
- China
- Prior art keywords
- mafg
- pcbp2
- bladder cancer
- iron
- fpn1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911159971.XA CN110806486B (zh) | 2019-11-23 | 2019-11-23 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911159971.XA CN110806486B (zh) | 2019-11-23 | 2019-11-23 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110806486A true CN110806486A (zh) | 2020-02-18 |
CN110806486B CN110806486B (zh) | 2023-03-21 |
Family
ID=69491215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911159971.XA Active CN110806486B (zh) | 2019-11-23 | 2019-11-23 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110806486B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114350798A (zh) * | 2021-12-28 | 2022-04-15 | 深圳市人民医院 | Linc00336在结肠癌的预后中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102238962A (zh) * | 2008-12-05 | 2011-11-09 | 伊莱利利公司 | 抗膜铁转运蛋白1单克隆抗体及其用途 |
WO2012009382A2 (en) * | 2010-07-12 | 2012-01-19 | The Regents Of The University Of Colorado | Molecular indicators of bladder cancer prognosis and prediction of treatment response |
US20130012409A1 (en) * | 2009-10-08 | 2013-01-10 | M Frank | Diagnostic and Prognostic Markers for Cancer |
CN103417968A (zh) * | 2012-05-18 | 2013-12-04 | 中国医学科学院基础医学研究所 | 聚胞嘧啶结合蛋白2抑制剂在制备治疗人神经胶质瘤的药物中的用途 |
KR20170136324A (ko) * | 2016-06-01 | 2017-12-11 | 부산대학교 산학협력단 | 페로포틴-1 억제제를 유효성분으로 포함하는 철대사 이상 질환의 예방 또는 치료용 조성물 |
CN108148909A (zh) * | 2016-12-02 | 2018-06-12 | 中国医学科学院肿瘤医院 | 一种结直肠癌预后早期预警的诊断试剂盒及其应用 |
WO2019052708A1 (en) * | 2017-09-15 | 2019-03-21 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM RESISTANT CANCER CELLS |
-
2019
- 2019-11-23 CN CN201911159971.XA patent/CN110806486B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102238962A (zh) * | 2008-12-05 | 2011-11-09 | 伊莱利利公司 | 抗膜铁转运蛋白1单克隆抗体及其用途 |
US20130012409A1 (en) * | 2009-10-08 | 2013-01-10 | M Frank | Diagnostic and Prognostic Markers for Cancer |
WO2012009382A2 (en) * | 2010-07-12 | 2012-01-19 | The Regents Of The University Of Colorado | Molecular indicators of bladder cancer prognosis and prediction of treatment response |
CN103417968A (zh) * | 2012-05-18 | 2013-12-04 | 中国医学科学院基础医学研究所 | 聚胞嘧啶结合蛋白2抑制剂在制备治疗人神经胶质瘤的药物中的用途 |
KR20170136324A (ko) * | 2016-06-01 | 2017-12-11 | 부산대학교 산학협력단 | 페로포틴-1 억제제를 유효성분으로 포함하는 철대사 이상 질환의 예방 또는 치료용 조성물 |
CN108148909A (zh) * | 2016-12-02 | 2018-06-12 | 中国医学科学院肿瘤医院 | 一种结直肠癌预后早期预警的诊断试剂盒及其应用 |
WO2019052708A1 (en) * | 2017-09-15 | 2019-03-21 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | MAFG AS A POTENTIAL THERAPEUTIC TARGET TO RESTORE CHEMOSENSITIVITY IN PLATINUM RESISTANT CANCER CELLS |
Non-Patent Citations (7)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114350798A (zh) * | 2021-12-28 | 2022-04-15 | 深圳市人民医院 | Linc00336在结肠癌的预后中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110806486B (zh) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Deng et al. | Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer | |
US8143228B2 (en) | Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment | |
Pan et al. | Elevated expression of semaphorin 5A in human gastric cancer and its implication in carcinogenesis | |
Yu et al. | CBX7 is a glioma prognostic marker and induces G1/S arrest via the silencing of CCNE1 | |
CN108410984B (zh) | Rbms3作为肿瘤耐药检测、治疗及预后分子靶点的应用 | |
Wu et al. | Up-regulation of CHAF1A, a poor prognostic factor, facilitates cell proliferation of colon cancer | |
CN110806486B (zh) | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 | |
Liu et al. | Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence | |
Zhang et al. | The LncRNA CASC11 promotes colorectal cancer cell proliferation and migration by adsorbing miR-646 and miR-381-3p to upregulate their target RAB11FIP2 | |
Gao et al. | miR-21-5p inhibits the proliferation, migration, and invasion of glioma by targeting S100A10 | |
Zhao et al. | AP2α negatively regulates PDHA1 in cervical cancer cells to promote aggressive features and aerobic glycolysis in vitro and in vivo | |
Jiang et al. | SP2509, a selective inhibitor of LSD1, suppresses retinoblastoma growth by downregulating β-catenin signaling | |
Wu et al. | TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma. | |
CN110846413B (zh) | Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用 | |
Fang et al. | Blocking TGF-β expression attenuates tumor growth in lung cancers, potentially mediated by skewing development of neutrophils | |
Zhang et al. | N-myc downstream-regulated gene 1 (NDRG1) regulates vascular endothelial growth factor a (VEGFA) and malignancies in glioblastoma multiforme (GBM) | |
CN112322730B (zh) | 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用 | |
CN114306611A (zh) | Abhd2基因表达抑制剂、其应用及药物 | |
Date et al. | Borealin is repressed in response to p53/Rb signaling | |
Liu et al. | Suppression of CCT3 inhibits melanoma cell proliferation by downregulating CDK1 expression | |
Chang et al. | Long non-coding RNA LINC00320 inhibits tumorigenicity of glioma cells and angiogenesis through downregulation of NFKB1-mediated AQP9 | |
CN110373468B (zh) | 泛素连接酶wdhd1作为靶位点在制备肺腺癌顺铂增敏药物中的应用 | |
CN110541029B (zh) | 乙醛脱氢酶18a1基因及其编码产物在mycn扩增神经母细胞瘤中的应用 | |
CN113101369B (zh) | 环状RNA circ-RNF13作为靶位点抑制剂的应用 | |
KR20210148772A (ko) | 대장암 환자의 진단 또는 예후 예측을 위한 tcof1의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Cao Ke Inventor after: Xiao Mengqing Inventor after: Xiang Liang Inventor after: He Dong Inventor after: Zhu Yuxing Inventor after: Zeng Qinghai Inventor before: Cao Ke Inventor before: Xiang Liang Inventor before: Xiao Mengqing Inventor before: He Dong Inventor before: Zhu Yuxing Inventor before: Zeng Qinghai |
|
GR01 | Patent grant | ||
GR01 | Patent grant |